Other substances

Efonidipine

A dihydropyridine calcium channel blocker.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Efonidipine is an experimental dihydropyridine calcium channel blocker. Its use in atherosclerosis and acute renal failure have been investigated (DrugBank).

Efonidipine on PubChem
Efonidipine on Wikipedia


Marketed as

LANDEL; NZ-105; SELEFODIPINE

 

Structure image - Efonidipine

CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
3CLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay 3.75

Inhibited the SARS-CoV-2 3C-like protease in vitro with IC50 below 38.5 μM.

 Oct/25/2020

AI-suggested references

Link Publication date
Instant determination of the artemisinin from various Artemisia annua L. extracts by LC-ESI-MS/MS and their in-silico modelling and in vitro antiviral activity studies against SARS-CoV-2
Sep/28/2021
Export (.csv)